Table 4. Incidence and type of acute toxicity developed in patients receiving postoperative chemoradiotherapy with capecitabine and concurrent IMRT/3D-CRT.
| Grade; | N (%) | |||
|---|---|---|---|---|
| Toxicity | 1 | 2 | 3 | 4 |
| Fatigue | 51 (22.4) | 3 (1.6) | 1 (0.5) | 0 (0) |
| Skin reaction | 57 (31) | 28 (15.2) | 4 (2.2) | 0 (0) |
| Anorexia | 54 (29.3) | 5 (2.7) | 0 (0) | 0 (0) |
| Nausea | 32 (17.4) | 4 (2.2) | 0 (0) | 0 (0) |
| Vomiting | 5 (2.7) | 2 (1.1) | 0 (0) | 0 (0) |
| Diarrhea | 33 (17.9) | 35 (19) | 41 (22.3) | 1 (0.5) |
| Tenesmus | 49 (26.6) | 16 (8.7) | 5 (2.7) | 0 (0) |
| Body weight decline | 18 (9.8) | 2 (1.1) | 0 (0) | 0 (0) |
| Food-hand syndrome | 0 (0) | 1 (0.5) | 0 (0) | 0 (0) |
| Leucopenia | 72 (39.1) | 42 (22.8) | 7 (3.8) | 0 (0) |
| Thrombocytopenia | 7 (3.8) | 2 (1.1) | 0 (0) | 0 (0) |
| ALT elevation | 10 (5.4) | 0 (0) | 0 (0) | 0 (0) |
| TBIL elevation | 8 (7.2) | 2 (1.1) | 0 (0) | 0 (0) |
Abbreviations: ALT, aminase; TBIL, total bilirubin level; IMRT, intensity-modulated radiotherapy; 3D-CRT, three-dimensional conformal radiotherapy.